Literature DB >> 31262669

POEMS Syndrome: Indian Experience From a Tertiary-Care Institute.

Raja Pramanik1, Aparna Sharma1, Atul Sharma1, Ajay Gogia1, Ranjit Kumar Sahoo1, Prabhat Singh Malik1, M V Padma2, Sunu Lazar Cyriac3, Lalit Kumar4.   

Abstract

INTRODUCTION: POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes) syndrome is a rare multisystem paraneoplastic syndrome characterized by peripheral neuropathy and monoclonal plasmacytosis. Retrospective institutional experiences from the Mayo Clinic as well as Chinese, European, and Japanese series have provided important insights into the characteristics and treatment of this disease, but Indian data are extremely limited. We retrospectively analyzed 49 cases from our institute including 10 patients who underwent autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS: We analyzed clinical and laboratory characteristics, treatment details and outcome of all patients diagnosed with POEMS syndrome between 1993 and 2017.
RESULTS: Complete medical records were available for 49 patients with a median age of 44 years. Male/female ratio was 38:11. Twenty patients (40.8%) had Eastern Cooperative Oncology Group performance status of 4. Before 2012, melphalan/prednisolone was the most common regimen provided, while bortezomib/dexamethasone and lenalidomide/dexamethasone were used later. Hematologic response was available for 40 patients, 15 (37.5%) of whom experienced complete response, 13 (32.5%) partial response, and 11 (27.5%) stable disease. The median modified Rankin score at baseline was 4 (range, 1-5), which improved to 3 (range, 1-5). Ten patients underwent consolidation ASCT after a median of 4 cycles of induction. Median melphalan dose was 140 mg/m2. Engraftment syndrome was observed in 4. After ASCT, all 10 patients experienced hematologic complete response and clinical improvement.
CONCLUSION: This retrospective analysis provides important information on the clinical characteristics of POEMS syndrome in Indian patients, which will help the clinician's decision-making process.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical; Myeloma; Outcome; Response assessment; Transplant

Year:  2019        PMID: 31262669     DOI: 10.1016/j.clml.2019.05.018

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  1 in total

Review 1.  Not the final diagnosis: from Addison's disease to POEMS syndrome: a case report and literature review.

Authors:  Xiaoxi Xie; Rao Li; Yongxia Lu; Xuan Li; Pu Kuang; Chunhui Wang; Nanwei Tong; Qingguo Lü
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.